The pharmacokinetics and pharmacodynamics of continuous infusion vancomycin in adult people with cystic fibrosis
Pediatric Pulmonology · 2024
DOI: 10.1002/ppul.26714 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Pulmonology, 2024. Verfasst von Bryn Lindley und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacotherapy, University of North Texas Health Science Center College of Pharmacy, Fort Worth, Texas, USA. Hauptthemen laut MEDLINE: Cystic Fibrosis, Methicillin-Resistant Staphylococcus aureus, Acute Kidney Injury, Staphylococcal Infections. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben. Gefördert von: None.
Abstract (Originalsprache)
Background
The American Thoracic Society Guidelines recommend vancomycin as first line option for treatment of methicillin‐resistant Staphylococcus aureus . Two studies have described the pharmacokinetics (PK) of intermittent intravenous (IV) vancomycin in adult people with cystic fibrosis (PwCF). Currently, there have not been any studies describing the PK of continuous infusion vancomycin in PwCF. Our study aimed to describe the PK of continuous infusion vancomycin in adult PwCF.
Methods
Included patients were adult PwCF, who were admitted to University of Utah Hospital between May 11, 2014 and August 31, 2020, and received continuous infusion vancomycin for the treatment of an pulmonary exacerbations. The primary outcome was to describe vancomycin clearance rate (CL vanco ) and total daily dose (TDD). Secondary outcomes included rates of acute kidney injury (AKI), liver injury, and infusion‐related reactions.
Results
Twenty patients were included in this study. The mean CL vanco was 5.08 L/h on Day 3 and 4.58 L/h on Day 7 ( p = .04), and the TDD increased from 2444 mg on Day 3 to 2556 on Day 7, although not statistically significant ( p = 0.26). Zero patients experienced an AKI, two patients experienced liver injury, and no patients experienced infusion‐related reactions.
Conclusions
This study demonstrates that continuous infusion vancomycin PK, namely CL vanco , is similar to previously reported CL vanco for intermittent dosed IV vancomycin in adult PwCF. This study suggests that continuous infusion vancomycin is likely safe to use in adult PwCF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacotherapy, University of North Texas Health Science Center College of Pharmacy, Fort Worth, Texas, USA.
- Department of Pharmacy, University of Utah Health, Salt Lake City, Utah, USA.
- University of Utah School of Medicine, Salt Lake City, Utah, USA.
- Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, Utah, USA.
ORCID-Profile: Bryn Lindley, David C Young
Förderung
- None
Zitieren
APA
Lindley, B., Bhakta, Z., Leclair, L., & Young, D. C. (2024). The pharmacokinetics and pharmacodynamics of continuous infusion vancomycin in adult people with cystic fibrosis. Pediatric Pulmonology. https://doi.org/10.1002/ppul.26714
Vancouver
Lindley B, Bhakta Z, Leclair L, Young DC. The pharmacokinetics and pharmacodynamics of continuous infusion vancomycin in adult people with cystic fibrosis. Pediatric Pulmonology. 2024. doi:10.1002/ppul.26714
BibTeX
@article{Lindley2024,
author = {Lindley, Bryn and Bhakta, Zubin and Leclair, Laurie and Young, David C},
title = {The pharmacokinetics and pharmacodynamics of continuous infusion vancomycin in adult people with cystic fibrosis},
journal = {Pediatric Pulmonology},
year = {2024},
doi = {10.1002/ppul.26714}
}
EUVIMED